An assessment of Ghana’s pilot of the RTS,S malaria vaccine implementation programme; 2019–2021: a retrospective study
Ghana's MVIP demonstrated remarkable strengths worth leveraging to improve the national immunization programme. The weaknesses observed in some of the thematic areas present opportunities to engage key immunization partners and stakeholders towards aligning efforts to ensure a more robust expansion phase. The lessons from the MVIP may be relevant to areas introducing malaria vaccine irrespective of the product type-RTS,S or R21.
Authors
- Patrick Kuma‐Aboagye
- Kwame Amponsa-Achiano (ORCID: https://orcid.org/0000-0001-8145-970X)
- George Bonsu
- Michael Rockson Adjei (ORCID: https://orcid.org/0000-0002-8813-1800)
- Peter Ofori Tweneboah
- Franklin Asiedu‐Bekoe (ORCID: https://orcid.org/0000-0002-0691-5020)
- Janet Vanessa Baafi
- Martin Peter Grobusch
- Sally-Ann Ohene
Institutions
- World Health Organization - Pakistan (PK)
- University of Cape Town (ZA)
- Centre de Recherche Médicales de Lambaréné (GA)
- Wellcome Centre for Infectious Diseases Research in Africa (ZA)
- Amsterdam University Medical Centers (NL)
- Ghana Health Service (GH)
- University of Tübingen (DE)
- University of Amsterdam (NL)
Publication Details
- Journal
- Malaria Journal
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1186/s12936-024-05113-8
- Citations
- 4
- Primary Topic
- Vaccine Coverage and Hesitancy
- Type
- article
- Field-Weighted Citation Impact
- 2.11